◀ Back to BCL2
BCL2 — CDK17
Text-mined interactions from Literome
Pathan et al., Neoplasia (New York, N.Y.) 2001
:
Comparison of a variety of pharmacological inhibitors of serine/threonine-specific protein kinases demonstrated that the
cyclin dependent kinase inhibitor, flavopiridol, selectively
blocks Bcl-2 phosphorylation induced by antimicrotubule drugs
Pathan et al., Neoplasia (New York, N.Y.) 2001
:
Comparison of a variety of pharmacological inhibitors of serine/threonine-specific protein kinases demonstrated that the
cyclin dependent kinase inhibitor, flavopiridol, selectively
blocks Bcl-2 phosphorylation induced by antimicrotubule drugs
Veliz et al., Cancer Control 2012
(Leukemia, Lymphocytic, Chronic, B-Cell...) :
These investigational agents include rituximab, alemtuzumab, ofatumumab, bendamustine, high-dose methylprednisolone, lenalidomide, lumiliximab,
cyclin dependent kinase inhibitors, small modular immunopharmaceuticals,
Bcl-2 inhibitors , and histone deacetylase inhibitors